All posts by medical

Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical…

May 28, 2020 medical

SHANGHAI, May27, 2020 /PRNewswire/ -- Shanghai Cell Therapy Group (SHCell) recently entered intoa six-year research collaborative project with Professor Qi-Long Ying from the University of Southern California (USC). Through the project, sponsored by $3.6 million from the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.

"Hematopoietic stem cells, or HSCs, are found in the bone marrow of adults," said Professor Qijun Qian, CEO of Shanghai Cell Therapy Group. "HSCs have the ability for long-term self-renewal and differentiation into various types of mature blood cells, and for rebuilding normal hematopoiesis and immune function in patients. They also have enormous potential to treat diseases, including tumors, autoimmune diseases, severe infectious disease, and inherited blood diseases, and to combat the effects of aging."

This research project will be conducted and supervised by Professor Qi-Long Ying, a Professor of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC. Professor Ying's pioneering stem cell research has won international acclaim, including the 2016 McEwen Award for Innovation, the highest honor in the field.

"We'll develop and optimize culture conditions for the long-term ex vivo expansion of HSCs," said Professor Ying. "We'll also test combinations of basal media, small molecules, cytokines and growth factors, and characterize ex vivo expanded hematopoietic stem and progenitor cells. These cells will then be genetically modified and tested for their potential to treat different diseases, including blood disorders and cancers."

Professor Andrew P. McMahon, Director of Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research of USC, added: "Stem cell biology represents an exciting area in medicine with great therapeutic potential. I am delighted SHCell is supporting Professor Ying. A breakthrough in the ability to propagate and manipulate HSCs will have lasting clinical significance."

The project also plans to build animal models of different blood diseases and cancers and test the safety and effectiveness of genetically modified hematopoietic stem and progenitor cells before clinical translation. SHCell will actively explore clinical applications of hematopoietic stem and progenitor cells in the treatment of cancers or blood diseases.

As SHCell's first overseas collaboration, this project aims to advance the goals of the Baize Plan: to provide first-class cell treatments and cell therapies at an affordable price to cure cancer and increase life expectancy. SHCell hopes that this project will also accelerate original scientific breakthroughs in the stem cell field.

Shanghai Cell Therapy Group

Founded in 2013, Shanghai Cell Therapeutics Group Co., Ltd is located at the Shanghai Municipal Engineering and Technology Research Center, which was established by the Shanghai Science and Technology Commission. With a mission of "changing the length and abundance of life with cell therapy", SHCell has created a closed-loop industrial chain and an integrated platform for cell treatment and cell therapy. It comprises cell storage, cell drug research and cell clinical transformation with cell therapy as its core business.

The Baize Plan was proposed in 2016 by Wu Mengchao, an Academician of the Chinese Academy of Sciences (CAS) and initiated by Professor Qian, aiming to provide first-class cell treatments and cell therapies at an affordable price with the goal of curing cancers and increasing life expectancy. The Baize Plan Fund was created by the Shanghai Cell Therapy Group to realize the vision of the Baize Plan.

University of Southern California (USC)

Founded in 1880, the University of Southern California is one of the world's leading educational and research institutions, and also the oldest private research university in California. Located in the heart of Los Angeles, the University of Southern California comprises 23 schools and units, and students are encouraged to explore different fields of study. The University of Southern California ranked #22 in National Universities in the 2020 edition of Best Colleges, published by U.S. News & World Report.

For more information, visit http://www.shcell.com/

See original here:
Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical...

Cell Biology

Alpacas and antibodies: How scientists hope to stop coronavirus in its tracks – Horizon magazine

May 28, 2020 medical

Researchers at the Karolinska Institute in Stockholm, Sweden, are optimistic that at least one of the 124 vaccines in the pipeline will succeed. However, a vaccine needs to be delivered to everyone, and scaling to more than 7 billion doses is extremely challenging. So they have set their research sights on a more accessible goal: neutralising antibodies that kill an infection after it has taken hold.

The project CoroNAb was established in mid-February when there were 1,000 known deaths from Covid-19 in the world. Containing the spread of the virus is not our primary objective that ship has sailed, said Dr Benjamin Murrell, assistant professor at the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute. Our aim is to find therapeutics to stop the progression of disease within a patient.

Therapeutics

These therapeutics will take the form of antibodies that are infused into a patient through a syringe. When someone is infected with the new SARS-CoV-2 coronavirus, they typically mount an antibody response against it, and in most cases these antibodies contribute to clearing the virus. However, infection-fighting antibodies produced in a lab can also be introduced into the body, resulting in passive immunisation.

So what differentiates a vaccine from imported antibodies?

Vaccines are given to people when they are well, prompting them to develop their own antibodies, whereas antibody therapy is administered when an infection has taken hold and a patient is struggling to mount their own immune response.

Monoclonal antibodies (mAbs) that is, antibodies that are identical clones of one another have emerged over the past few decades as effective therapies for various medical conditions, including cancers and autoimmune disorders. Increasingly, they are also considered a major medical tool to fight severe viral infections such as Covid-19 though to date, only one mAb been approved for this purpose. Many more are in clinical trials, including one that Dr Murrell has been working on.

At what stage of an infection, exactly, a coronavirus patient would be treated with mAbs remains to be seen. This will need to be studied in animal models, or directly in human trials, said Dr Murrell, who is coordinating the CoroNAb project together with partners in Denmark, Switzerland, and the UK.

Maybe you can treat someone with monoclonal antibody therapy late in infection and still stop deterioration, but perhaps not, he said.

The CoroNAb team at the Karolinska Institute is creating mAbs from animals. An animal is given a specific viral antigen (the molecules that interact with a bodys antibodies) and an immune response is provoked, leading to some of the animals immune cells producing antibodies. The cells harbouring these antibodies are then isolated and the genetic sequence of the antibody is cloned from each cell into a circular form of DNA that allows the antibodies to be produced in the lab.

Since the potency of the antibodies discovered is at least partly down to chance, it makes sense for many groups to be going after the same goal.

Dr Benjamin Murrell, Karolinska Institute in Stockholm, Sweden

Alpacas

The Stockholm team is focusing its research efforts on mice, rhesus macaques and alpacas. Alpacas are camelids (like camels and llamas) producing particularly interesting antibody fragments, known as single domain antibodies, which allow for fast antibody discovery and large-scale antibody production, which is why they are favoured by the CoroNAb team.

One month into the project, these mammals have been injected with lab-created variants of the coronaviruss spike proteins, and preliminary indications suggest that all animal groups are responding well. Mining the alpaca antibody repertoire is currently underway. Over the next few weeks, the researchers will be testing the neutralising activity of the produced antibodies against SARS-CoV-2.

Dr Murrell said: The coming weeks are both critical and uncertain. Depending on these first results, well either get lucky, or we might have to take a few steps back and repeat.

Despite all the unknowns, Dr Murrell is confident that neutralising antibodies will emerge from this research. We will make something work, he said. The question is, will an effective antibody discovered by the CoroNAb team become a useful addition to Europes arsenal of SARS-CoV-2 treatments? Labs around the world are chasing the same prize, working night and day to identify effective antibodies against Covid-19, with some early results already emerging.

To make a contribution in this climate, an antibody will need to have a strong edge over its competition. If one groups antibody turns out to be 10 times more potent than the next best, you might have to produce far less of it for an effective therapy, reducing the manufacturing burden, explained Dr Murrell. He added, Since the potency of the antibodies discovered is at least partly down to chance, it makes sense for many groups to be going after the same goal.

Bacterium

Professor Luis Serrano from the Centre for Genomic Regulation (CRG) in Spain leads another team engaged in the race against Covid-19. His lab is both supporting global vaccine efforts and probing novel, non-vaccine mechanisms to limit the death toll.

Until two months ago, Prof. Serrano was engaged in the MycoSynVac project, which investigated ways to enlist cellular hosts to transport vaccines around the body. Cellular hosts (known in the field of synthetic biology as chassis) hold great promise as low-cost, scalable and potentially game-changing systems for the targeted delivery of life-saving vaccines.

The chosen chassis in Serranos five-year project was a modified form of the bacterium Mycoplasma pneumoniae, which causes respiratory infections. By the projects conclusion, the researchers were able to show that Mycoplasma makes an excellent universal chassis meaning all manner of vaccines can safely hitch a ride off it.

Prof. Serrano is optimistic that a vaccine for Covid-19, when it arises, will be among the ingredients that can be safely delivered by his Mycoplasma chassis. The team is in the early stages of testing this hypothesis. Over the next month or so, they will insert synthetic copies of key coronavirus genes into bacterial cells, in the hope that those surface proteins belonging to the virus will trigger a protective immune response from the human body.

As it is engineered from a bacterium that targets the lungs, the chassis may be capable of even more than vaccine transportation, according to Prof. Serrano. We think it can deliver therapeutic molecules directly to receptors in the lungs, he said.

These molecules would either counteract inflammation or stop the virus from binding to the alveoli (the cells through which oxygen flows from lungs to bloodstream) by blocking the viral cell receptors, he explains.

With the virus blocked or lung damage repaired, a patient who is not responding to conventional treatments might be spared the worst symptoms of a Covid-19 infection, such as a devastating cytokine storm, where the body mounts a massive, and potentially deadly, immune response an overreaction triggered by pneumonia.

Spray

The idea is to create a spray to deliver our engineered bacteria directly to the lungs, where it will express locally what is needed the active molecules and later it will be washed away naturally, explained Prof. Serrano.

He added: There are clear advantages to this direct approach. If you apply a drug systemically (affecting the whole body), it might be beneficial where its needed but it might also have dangerous effects on other tissue.

Price is another major benefit to recruiting bacteria to deliver life-saving medications. Producing therapeutic molecules synthetically is expensive. For a fraction of the cost, a host cell can be cloned to produce vast populations of cells containing the same therapeutic molecules.

In the labs of their spin-off company Pulmobiotics, Prof. Serranos team is exposing coronavirus proteins to molecules with known anti-inflammatory qualities, to test the molecules effectiveness against the virus. They are also engineering mutations of these molecules, hoping to increase the affinity between molecule and human receptor proteins. Data from these experiments is expected by mid-summer.

Prof Serrano is hopeful that his research will yield positive results, however these may not come in time to save lives during the current outbreak. By the time we get (regulatory) approval, the Covid situation may have been resolved, he said. But this research will open the way for future therapies during future pandemics.

The research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.

Cell Biology

Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis – Bangor Daily News

May 28, 2020 medical

BAR HARBOR Research by scientists at the MDI Biological Laboratoryis opening up new approaches to promoting tissue regeneration in organs damaged by disease or injury.

In recent years, research in regenerative biology has focused on stem cell therapies that reprogram the bodys own cells to replace damaged tissue, which is a complicated process because it involves turning genes in the cells nucleus on and off.

A recent paper in the journal Genetics by MDI Biological Laboratory scientist Elisabeth Marnik, Ph.D., a postdoctoral fellow in the laboratory of Dustin Updike, Ph.D., offers insight into an alternate pathway to regeneration: by recreating the properties of germ cells.

Germ cells, which are the precursors to the sperm and egg, are considered immortal because they are the only cells in the body with the potential to create an entirely new organism. The stem cell-like ability of germ cells to turn into any type of cell is called totipotency.

By getting a handle on what makes germ cells totipotent, we can promote regeneration by unlocking the stem cell-like properties of other cell types, said Updike. Our research shows that such cells can be reprogrammed by manipulating their cytoplasmic composition and chemistry, which would seem to be safer and easier than changing the DNA within a cells nucleus.

Using the tiny, soil-dwelling nematode worm, C. elegans, as a model, the Updike lab studies organelles called germ granules that reside in the cytoplasm (the contents of the cell outside of the nucleus) of germ cells. These organelles, which are conserved from nematodes to humans, are one of the keys to the remarkable attributes of germ cells, including the ability to differentiate into other types of cells.

In their recent paper entitled Germline Maintenance Through the Multifaceted Activities of GLH/Vasa in Caenorhabditis elegans P Granules, Updike and his team describe the intriguing and elusive role of Vasa proteins within germ granules in determining whether a cell is destined to become a germ cell with totipotent capabilities or a specific type of cell, like those that comprise muscle, nerves or skin.

Because of the role of Vasa proteins in preserving totipotency, an increased understanding of how such proteins work could lead to unprecedented approaches to de-differentiating cell types to promote regeneration; or alternatively, to new methods to turn off totipotency when it is no longer desirable, as in the case of cancer.

The increase in chronic and degenerative diseases caused by the aging of the population is driving demand for new therapies, said MDI Biological Laboratory President Hermann Haller, M.D. Dustins research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent, as well as an increased understanding of cancer.

Because of the complexity of the cellular chemistry, research on Vasa and other proteins found in germ granules is often overlooked, but that is rapidly changing especially among pharmaceutical companies as more scientists realize the impact and potential of such research, not only for regenerative medicine but also for an understanding of tumorigenesis, or cancer development, Updike said.

Recent research has found that some cancers are accompanied by the mis-expression of germ granule proteins, which are normally found only in germ cells. The mis-expression of these germ-granule proteins seems to promote the immortal properties of germ cells, and consequently tumorigenesis, with some germ-granule proteins now serving as prognosis markers for different types of cancer, Updike said.

Updike is a former postdoctoral researcher in the laboratory of Susan Strome, Ph.D., at University of California, Santa Cruz. Strome, who was inducted into the National Academy of Sciences last year, first discovered P granules more than 30 years ago. She credits Updike, who has published several seminal papers on the subject, with great imagination, determination and excellent technical skill in the pursuit of his goal of elucidating the function and biochemistry of these tiny organelles.

The lead author of the new study from the Updike laboratory, Elisabeth A. Marnik, Ph.D., will be launching her own laboratory at Husson University in Bangor, Maine, this fall. Other contributors include J. Heath Fuqua, Catherine S. Sharp, Jesse D. Rochester, Emily L. Xu and Sarah E. Holbrook. Their research was conducted at the Kathryn W. Davis Center for Regenerative Biology and Medicine at the MDI Biological Laboratory.

Updikes research is supported by a grant (R01 GM-113933) from the National Institute of General Medical Sciences (NIGMS), an institute of the National Institutes of Health (NIH). The equipment and cores used for part of the study were supported by NIGMS-NIH Centers of Biomedical Research Excellence and IDeA Networks of Biomedical Research Excellence grants P20 GM-104318 and P20 GM-203423, respectively.

We aim to improve human health and healthspan by uncovering basic mechanisms of tissue repair, aging and regeneration, translating our discoveries for the benefit of society and developing the next generation of scientific leaders. For more information, please visitmdibl.org.

Go here to read the rest:
Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis - Bangor Daily News

Cell Biology

Life Science Tools & Reagents Market Brief Analysis and Application, Growth by 2026 – News Distinct

May 28, 2020 medical

QY Research as of late produced a research report titled, Life Science Tools & Reagents . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Life Science Tools & Reagents market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Life Science Tools & Reagents market are: , Abbott Laboratories, Abcam, BD Biosciences, Beckman Coulter Inc., Benitec, Bio-Rad Laboratories, Cell Sciences, Cell Signaling Technology, Cepheid Inc., Charles River Laboratories International Inc., Echelon Biosciences Inc., Emd Millipore, Enzo Biochem, High Throughput Genomics Inc., Illumina Inc., Lifesensors Inc., Lonza Group AG, Luminex Corp., Stemgent, Sysmex-Partec Gmbh, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Tocris Bioscience (Bio-Techne), Vitro Diagnostics Inc., Waters Corp., Xenotech Llc

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1540823/global-life-science-tools-amp-reagents-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Life Science Tools & Reagents Market Segment By Type:

, Tools, Reagents

Global Life Science Tools & Reagents Market Segment By Application:

, Proteomics, Cell biology research, Epigenetics, Metabolomics, Bioinformatics, Others

Competitive Landscape

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key companies operating in the global Life Science Tools & Reagents market include , Abbott Laboratories, Abcam, BD Biosciences, Beckman Coulter Inc., Benitec, Bio-Rad Laboratories, Cell Sciences, Cell Signaling Technology, Cepheid Inc., Charles River Laboratories International Inc., Echelon Biosciences Inc., Emd Millipore, Enzo Biochem, High Throughput Genomics Inc., Illumina Inc., Lifesensors Inc., Lonza Group AG, Luminex Corp., Stemgent, Sysmex-Partec Gmbh, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Tocris Bioscience (Bio-Techne), Vitro Diagnostics Inc., Waters Corp., Xenotech Llc

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1540823/global-life-science-tools-amp-reagents-market

TOC

Table of Contents 1 Life Science Tools & Reagents Market Overview1.1 Life Science Tools & Reagents Product Overview1.2 Life Science Tools & Reagents Market Segment by Type1.2.1 Tools1.2.2 Reagents1.3 Global Life Science Tools & Reagents Market Size by Type (2015-2026)1.3.1 Global Life Science Tools & Reagents Market Size Overview by Type (2015-2026)1.3.2 Global Life Science Tools & Reagents Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Life Science Tools & Reagents Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Life Science Tools & Reagents Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Life Science Tools & Reagents Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Life Science Tools & Reagents Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Life Science Tools & Reagents Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Life Science Tools & Reagents Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Life Science Tools & Reagents Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.2 Europe Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.4 Latin America Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Life Science Tools & Reagents Sales Breakdown by Type (2015-2026) 2 Global Life Science Tools & Reagents Market Competition by Company2.1 Global Top Players by Life Science Tools & Reagents Sales (2015-2020)2.2 Global Top Players by Life Science Tools & Reagents Revenue (2015-2020)2.3 Global Top Players Life Science Tools & Reagents Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Life Science Tools & Reagents Manufacturing Base Distribution, Sales Area, Product Type2.5 Life Science Tools & Reagents Market Competitive Situation and Trends2.5.1 Life Science Tools & Reagents Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Life Science Tools & Reagents Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Life Science Tools & Reagents as of 2019)2.7 Date of Key Manufacturers Enter into Life Science Tools & Reagents Market2.8 Key Manufacturers Life Science Tools & Reagents Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Life Science Tools & Reagents Status and Outlook by Region (2015-2026)3.1 Global Life Science Tools & Reagents Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Life Science Tools & Reagents Market Size Market Share by Region (2015-2020)3.2.1 Global Life Science Tools & Reagents Sales Market Share by Region (2015-2020)3.2.2 Global Life Science Tools & Reagents Revenue Market Share by Region (2015-2020)3.2.3 Global Life Science Tools & Reagents Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Life Science Tools & Reagents Market Size Market Share by Region (2021-2026)3.3.1 Global Life Science Tools & Reagents Sales Market Share by Region (2021-2026)3.3.2 Global Life Science Tools & Reagents Revenue Market Share by Region (2021-2026)3.3.3 Global Life Science Tools & Reagents Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.4.1 North America Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.4.2 North America Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.5 Asia-Pacific Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.6 Europe Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.6.1 Europe Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.6.2 Europe Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.7 Latin America Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.7.1 Latin America Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.7.2 Latin America Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.8 Middle East and Africa Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Life Science Tools & Reagents Sales YoY Growth (2015-2026) 4 Global Life Science Tools & Reagents by Application4.1 Life Science Tools & Reagents Segment by Application4.1.1 Proteomics4.1.2 Cell biology research4.1.3 Epigenetics4.1.4 Metabolomics4.1.5 Bioinformatics4.1.6 Others4.2 Global Life Science Tools & Reagents Sales by Application: 2015 VS 2020 VS 20264.3 Global Life Science Tools & Reagents Historic Sales by Application (2015-2020)4.4 Global Life Science Tools & Reagents Forecasted Sales by Application (2021-2026)4.5 Key Regions Life Science Tools & Reagents Market Size by Application4.5.1 North America Life Science Tools & Reagents by Application4.5.2 Europe Life Science Tools & Reagents by Application4.5.3 Asia-Pacific Life Science Tools & Reagents by Application4.5.4 Latin America Life Science Tools & Reagents by Application4.5.5 Middle East and Africa Life Science Tools & Reagents by Application 5 North America Life Science Tools & Reagents Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Life Science Tools & Reagents Sales Market Share by Country (2015-2020)5.1.2 North America Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Life Science Tools & Reagents Sales Market Share by Country (2021-2026)5.2.2 North America Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Life Science Tools & Reagents Market Size YoY Growth (2015-2026)5.3.2 Canada Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 6 Europe Life Science Tools & Reagents Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Life Science Tools & Reagents Sales Market Share by Country (2015-2020)6.1.2 Europe Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Life Science Tools & Reagents Sales Market Share by Country (2021-2026)6.2.2 Europe Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.2 France Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.3 U.K. Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.4 Italy Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.5 Russia Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 7 Asia-Pacific Life Science Tools & Reagents Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Life Science Tools & Reagents Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Life Science Tools & Reagents Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.2 Japan Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.3 South Korea Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.4 India Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.5 Australia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.6 Taiwan Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.7 Indonesia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.8 Thailand Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.9 Malaysia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.10 Philippines Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.11 Vietnam Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 8 Latin America Life Science Tools & Reagents Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Life Science Tools & Reagents Sales Market Share by Country (2015-2020)8.1.2 Latin America Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Life Science Tools & Reagents Sales Market Share by Country (2021-2026)8.2.2 Latin America Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Life Science Tools & Reagents Market Size YoY Growth (2015-2026)8.3.2 Brazil Life Science Tools & Reagents Market Size YoY Growth (2015-2026)8.3.3 Argentina Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 9 Middle East and Africa Life Science Tools & Reagents Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Life Science Tools & Reagents Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Life Science Tools & Reagents Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Life Science Tools & Reagents Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)9.3.3 U.A.E Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Life Science Tools & Reagents Business10.1 Abbott Laboratories10.1.1 Abbott Laboratories Corporation Information10.1.2 Abbott Laboratories Description, Business Overview and Total Revenue10.1.3 Abbott Laboratories Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.1.4 Abbott Laboratories Life Science Tools & Reagents Products Offered10.1.5 Abbott Laboratories Recent Development10.2 Abcam10.2.1 Abcam Corporation Information10.2.2 Abcam Description, Business Overview and Total Revenue10.2.3 Abcam Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.2.5 Abcam Recent Development10.3 BD Biosciences10.3.1 BD Biosciences Corporation Information10.3.2 BD Biosciences Description, Business Overview and Total Revenue10.3.3 BD Biosciences Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.3.4 BD Biosciences Life Science Tools & Reagents Products Offered10.3.5 BD Biosciences Recent Development10.4 Beckman Coulter Inc.10.4.1 Beckman Coulter Inc. Corporation Information10.4.2 Beckman Coulter Inc. Description, Business Overview and Total Revenue10.4.3 Beckman Coulter Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.4.4 Beckman Coulter Inc. Life Science Tools & Reagents Products Offered10.4.5 Beckman Coulter Inc. Recent Development10.5 Benitec10.5.1 Benitec Corporation Information10.5.2 Benitec Description, Business Overview and Total Revenue10.5.3 Benitec Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.5.4 Benitec Life Science Tools & Reagents Products Offered10.5.5 Benitec Recent Development10.6 Bio-Rad Laboratories10.6.1 Bio-Rad Laboratories Corporation Information10.6.2 Bio-Rad Laboratories Description, Business Overview and Total Revenue10.6.3 Bio-Rad Laboratories Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.6.4 Bio-Rad Laboratories Life Science Tools & Reagents Products Offered10.6.5 Bio-Rad Laboratories Recent Development10.7 Cell Sciences10.7.1 Cell Sciences Corporation Information10.7.2 Cell Sciences Description, Business Overview and Total Revenue10.7.3 Cell Sciences Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.7.4 Cell Sciences Life Science Tools & Reagents Products Offered10.7.5 Cell Sciences Recent Development10.8 Cell Signaling Technology10.8.1 Cell Signaling Technology Corporation Information10.8.2 Cell Signaling Technology Description, Business Overview and Total Revenue10.8.3 Cell Signaling Technology Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.8.4 Cell Signaling Technology Life Science Tools & Reagents Products Offered10.8.5 Cell Signaling Technology Recent Development10.9 Cepheid Inc.10.9.1 Cepheid Inc. Corporation Information10.9.2 Cepheid Inc. Description, Business Overview and Total Revenue10.9.3 Cepheid Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.9.4 Cepheid Inc. Life Science Tools & Reagents Products Offered10.9.5 Cepheid Inc. Recent Development10.10 Charles River Laboratories International Inc.10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Life Science Tools & Reagents Product Category, Application and Specification10.10.3 Charles River Laboratories International Inc. Life Science Tools & Reagents Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Charles River Laboratories International Inc. Recent Development10.11 Echelon Biosciences Inc.10.11.1 Echelon Biosciences Inc. Corporation Information10.11.2 Echelon Biosciences Inc. Description, Business Overview and Total Revenue10.11.3 Echelon Biosciences Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.11.4 Echelon Biosciences Inc. Life Science Tools & Reagents Products Offered10.11.5 Echelon Biosciences Inc. Recent Development10.12 Emd Millipore10.12.1 Emd Millipore Corporation Information10.12.2 Emd Millipore Description, Business Overview and Total Revenue10.12.3 Emd Millipore Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.12.4 Emd Millipore Life Science Tools & Reagents Products Offered10.12.5 Emd Millipore Recent Development10.13 Enzo Biochem10.13.1 Enzo Biochem Corporation Information10.13.2 Enzo Biochem Description, Business Overview and Total Revenue10.13.3 Enzo Biochem Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.13.4 Enzo Biochem Life Science Tools & Reagents Products Offered10.13.5 Enzo Biochem Recent Development10.14 High Throughput Genomics Inc.10.14.1 High Throughput Genomics Inc. Corporation Information10.14.2 High Throughput Genomics Inc. Description, Business Overview and Total Revenue10.14.3 High Throughput Genomics Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.14.4 High Throughput Genomics Inc. Life Science Tools & Reagents Products Offered10.14.5 High Throughput Genomics Inc. Recent Development10.15 Illumina Inc.10.15.1 Illumina Inc. Corporation Information10.15.2 Illumina Inc. Description, Business Overview and Total Revenue10.15.3 Illumina Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.15.4 Illumina Inc. Life Science Tools & Reagents Products Offered10.15.5 Illumina Inc. Recent Development10.16 Lifesensors Inc.10.16.1 Lifesensors Inc. Corporation Information10.16.2 Lifesensors Inc. Description, Business Overview and Total Revenue10.16.3 Lifesensors Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.16.4 Lifesensors Inc. Life Science Tools & Reagents Products Offered10.16.5 Lifesensors Inc. Recent Development10.17 Lonza Group AG10.17.1 Lonza Group AG Corporation Information10.17.2 Lonza Group AG Description, Business Overview and Total Revenue10.17.3 Lonza Group AG Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.17.4 Lonza Group AG Life Science Tools & Reagents Products Offered10.17.5 Lonza Group AG Recent Development10.18 Luminex Corp.10.18.1 Luminex Corp. Corporation Information10.18.2 Luminex Corp. Description, Business Overview and Total Revenue10.18.3 Luminex Corp. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.18.4 Luminex Corp. Life Science Tools & Reagents Products Offered10.18.5 Luminex Corp. Recent Development10.19 Stemgent10.19.1 Stemgent Corporation Information10.19.2 Stemgent Description, Business Overview and Total Revenue10.19.3 Stemgent Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.19.4 Stemgent Life Science Tools & Reagents Products Offered10.19.5 Stemgent Recent Development10.20 Sysmex-Partec Gmbh10.20.1 Sysmex-Partec Gmbh Corporation Information10.20.2 Sysmex-Partec Gmbh Description, Business Overview and Total Revenue10.20.3 Sysmex-Partec Gmbh Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.20.4 Sysmex-Partec Gmbh Life Science Tools & Reagents Products Offered10.20.5 Sysmex-Partec Gmbh Recent Development10.21 Thermo Fisher Scientific Inc.10.21.1 Thermo Fisher Scientific Inc. Corporation Information10.21.2 Thermo Fisher Scientific Inc. Description, Business Overview and Total Revenue10.21.3 Thermo Fisher Scientific Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.21.4 Thermo Fisher Scientific Inc. Life Science Tools & Reagents Products Offered10.21.5 Thermo Fisher Scientific Inc. Recent Development10.22 Trilink Biotechnologies10.22.1 Trilink Biotechnologies Corporation Information10.22.2 Trilink Biotechnologies Description, Business Overview and Total Revenue10.22.3 Trilink Biotechnologies Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.22.4 Trilink Biotechnologies Life Science Tools & Reagents Products Offered10.22.5 Trilink Biotechnologies Recent Development10.23 Tocris Bioscience (Bio-Techne)10.23.1 Tocris Bioscience (Bio-Techne) Corporation Information10.23.2 Tocris Bioscience (Bio-Techne) Description, Business Overview and Total Revenue10.23.3 Tocris Bioscience (Bio-Techne) Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.23.4 Tocris Bioscience (Bio-Techne) Life Science Tools & Reagents Products Offered10.23.5 Tocris Bioscience (Bio-Techne) Recent Development10.24 Vitro Diagnostics Inc.10.24.1 Vitro Diagnostics Inc. Corporation Information10.24.2 Vitro Diagnostics Inc. Description, Business Overview and Total Revenue10.24.3 Vitro Diagnostics Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.24.4 Vitro Diagnostics Inc. Life Science Tools & Reagents Products Offered10.24.5 Vitro Diagnostics Inc. Recent Development10.25 Waters Corp.10.25.1 Waters Corp. Corporation Information10.25.2 Waters Corp. Description, Business Overview and Total Revenue10.25.3 Waters Corp. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.25.4 Waters Corp. Life Science Tools & Reagents Products Offered10.25.5 Waters Corp. Recent Development10.26 Xenotech Llc10.26.1 Xenotech Llc Corporation Information10.26.2 Xenotech Llc Description, Business Overview and Total Revenue10.26.3 Xenotech Llc Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.26.4 Xenotech Llc Life Science Tools & Reagents Products Offered10.26.5 Xenotech Llc Recent Development 11 Life Science Tools & Reagents Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Life Science Tools & Reagents Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Life Science Tools & Reagents Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:
Life Science Tools & Reagents Market Brief Analysis and Application, Growth by 2026 - News Distinct

Cell Biology

Benchling, BERG, Thermo Fisher Scientific, And More: News From May 2020 – Bio-IT World

May 28, 2020 medical

May 27, 2020 |May featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Benchling, BERG, Thermo Fisher Scientific, and more.

Benchlingannounced the launch ofBenchling Insights, a new solution that gives life sciences companies the ability to query, visualize and collaborate around high quality, structured data that resides on the platform. While the biotech industry continues to grow, companies are faced with increased competition, patent expirations and increased scrutiny over pricing and efficacy. Biotech companies are under immense pressure to deliver new products into clinical evaluation faster than ever, which requires disciplined execution, a high degree of collaboration and unfettered access to data across the R&D lifecycle, saidSaji Wickramasekara, CEO and Co-Founder of Benchling, in a press release. We launched Benchling Insights so that our customers can make intelligent decisions with a complete view of their experimental and operational data. Analyses and dashboards can be rapidly created and shared across programs, teams, and leadership so companies can reach breakthroughs faster. Benchling Insights extends the Benchling Life Sciences R&D Cloudwith an integrated solution for data querying, visualization, and collaboration. Scientists can tailor advanced queries to visualize scientific and operational metrics, and use these to quickly answer key questions about their programs. For example, they can assess which cell lines generate the best assay performance, or which process variants lead to optimal outputs. R&D leaders can use centralized data to track overall pipeline performance and remove operational bottlenecks, while IT leaders can track product utilization and compliance. Press release

BERGannounced a new collaboration with Boehringer Ingelheimaround understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. The pilot program with Boehringer Ingelheim will work to reveal novel insights into the complexities of various inflammatory diseases. The potential outcomes of this partnership could lead to a broader understanding of the etiology of potential candidate biomarkers. BERG has previously collaborated with multiple pharmaceutical companies and applied its Interrogative Biologyplatform to diverse datasets to address major clinical unmet needs. Were excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim's translational medicine and biomarker expertise with BERGs next generation AI-driven, patient-biology capability, Niven R. Narain, BERG Co-founder, President and Chief Executive Officer, said in a press release. Our intent is for BERGs Interrogative Biology platform to enable the discoveryofbiomarkersthat willrevolutionize how to diagnose and treat patients with inflammatory diseases. Press release

Thermo Fisher Scientificreleased the Thermo Scientific Helios 5 Laser PFIBsystem, an advanced focused ion beam scanning electron microscope (FIB-SEM) with a fully integrated femtosecond laser that quickly characterizes millimeter-scale volumes of material in 3D with nanometer resolution. The Helios 5 Laser PFIB combines the best-in-class Thermo Scientific Elstar SEM Columnfor ultra-high-resolution imaging and advanced analytical capabilities with a plasma FIB column for top performance at all operating conditions, and a femtosecond laser that enables in-situ ablation at material removal rates not previously obtained by a commercially available product. The Helios 5 Laser PFIB is part of the fifth generation of the industry-leading Helios family. The Helios 5 Laser PFIB dramatically accelerates the pace of research for both academic and industrial users, allowing them to characterize materials in a matter of minutes versus the days it took before,Rosy Lee, vice president of materials science at Thermo Fisher, said in a press release. Not only can researchers quickly and accurately image statistically relevant, site-specific, millimeter-size cross-sections at nanoscale resolution, they can also set up large-volume 3D analyses to be automatically completed overnight, freeing up the microscope for other uses. The Helios 5 Laser PFIB allows researchers to obtain accurate large-volume 3D and sub-surface data up to 15,000 times faster than a typical Gallium ion source focused ion beam (Ga-FIB). For many materials, a large cross-section of hundreds of microns can be milled by the Helios 5 Laser PFIB in less than 5 minutes. Serial-section tomography is now possible with this combination of Laser and Plasma FIB, and when combined with EDS and EBSD detectors, can be extended to 3D elemental and grain orientation analysis at the millimeter scale. Press release

Following the recent launch of NVIDIAs new DGX A100system, NetApp ONTAP AIannounced it will be among the first converged AI stacks to incorporate the DGX A100 and NVIDIA Mellanox networking. NetApp and NVIDIA have been collaborating for several years to deliver AI solutions that help enterprises accelerate AI adoption. Both companies are working on eliminating AI bottlenecks and advancing the realm of possibilities, Kim Stevenson, Sr. Vice President and General Manager, Foundational Data Services Business Unit, NetApp, said in an official statement. NetApps full stack AI/ML/DL platforms delivered at the edge, core and cloud with ONTAP AI complements NVIDIAs rapidly expanding ecosystem of AI hardware, software, and development toolkits. Blog post

Advanced Biological Laboratories (ABL)announced the CE-IVDmarking of its DeepChek-HIVAssays is now available for in-vitro diagnostics. Intended to be used on HIV-1 Group M viruses from patients diagnosed with HIV infection, the assays deliver standardized, open and flexible solution suited to clinical settings performing sequencing through Capillary Electrophoresis and Next Generation Sequencing (NGS) systems. The DeepChek-HIV CE IVD Assays are covering respectively the Protease / Reverse Transcriptase and the Integrase regions of the virus and are intended to be used from input RNA extracted from plasma, serum or whole blood samples. Both assays are highly sensitive and have been validated to process clinical samples as low as 1,000 copies/mL with outstanding performances (100% agreement of analytical reproducibility and repeatability, 100% clinical reproducibility, 99% clinical sensitivity) in all three regions. Open and flexible, the DeepChek-HIV CE IVD Assays is a unique and versatile system that can be used under a large variety of laboratory throughput configurations. Obtaining CE IVD marking for our DeepChek-HIV assays will allow virology labs to access a unique and innovative technology, for HIV genotyping diagnostics. ABL will keep standardizing its entire portfolio of applications in virology and microbiology following European and International guidelines to improve the management of patients suffering from chronic diseases on a worldwide basis, Chalom Sayada, CEO of ABL, said in an official statement. Press release

Cardinal Healthand Vinetiannounced a collaboration to support cell and gene therapy manufacturers with a fully integrated solution that aligns logistics and commercialization services with digital Chain of Identityand Chain of Custodythroughout the treatment journey. Cardinal Healthsupports the cell and gene therapy market with a robust suite of services that includes end-to-end logistics, regulatory strategy, order-to-cash management and patient access and support services. Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for cell and gene therapies. The Vineti platform delivers digital Chain of Identity and Chain of Custody, providing essential patient safety and regulatory compliance across the value chain.Together, Cardinal Health and Vineti will develop best-in-class solutions to support the distribution of transformative, personalized therapies for cancer and other serious diseases.Specifically, Cardinal Health and Vineti will focus on integrated solutions that enable cell and gene therapy manufacturers to accelerate the commercialization of their products, while delivering a more simple, seamless and secure experience to hospitals and patients, from initial patient enrollment through delivery of the final dose of therapy and beyond. Press release

Immunailaunched out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. The company is also announcing $20M in seed funding, which will be used to further the development of its technology and business functions while expanding its team of scientists, engineers, and machine learning experts. Cell therapies and cancer immunotherapies have revolutionized medicine in the last few years and are expected to continue for the near future. However, due to the incredible complexity of the immune systemits trillions of cells partitioned into hundreds of cell types and states and how they interplay with other cells and proteinsit is prohibitively hard to predict how drugs will affect immune cells. For cell therapies with high manufacturing costs, a slight variation in cell therapy products can have a significant influence on a patients response to the therapy.Immunai has developed a vertically-integrated platform for multi-omic single-cell profiling that offers a broader view of the immune system in states of health, disease, and treatment to examine the bodys response to stimulus. With Immunais platform, pharmaceutical companies can identify more subtle nuances in cell abundances and cell function and mechanisms of action and biomarkers for toxicity response to accurately measure the efficacy of immunotherapies. For cell therapies, in particular, Immunai partners with cell therapy companies to understand cellular products sub-populations in unprecedented detail before and after infusion.Press release

Neuroscience

Trouble sleeping? The coronavirus pandemic could be wreaking havoc on your sleep cycles – Minnesota Public Radio News

May 27, 2020 medical

Are you having trouble sleeping? Are you having strange, vivid dreams?

Youre not alone.

Dr. Roxanne Prichard, professor of neuroscience and psychology at the University of St. Thomas, says that when we are under more stress, we are more likely to remember our dreams because we wake up more often.

Two experts discuss how our dreams and our sleep are being affected by the coronavirus pandemic.

Guests:

Dr. Roxanne Prichard is a professor of neuroscience and psychology at the University of St. Thomas. Her research focuses on adolescent sleep.

Dr. Ranji Varghese is the medical director at the Minnesota Regional Sleep Disorders Center at Hennepin Healthcare. He is also a psychiatrist and an assistant professor at the University of Minnesota, where he treats sleep disorders.

Use the audio player above to listen to the program.

Subscribe to the MPR News with Angela Davis podcast on: Apple Podcasts, Google Podcasts, Spotify or RSS.

The rest is here:
Trouble sleeping? The coronavirus pandemic could be wreaking havoc on your sleep cycles - Minnesota Public Radio News

Neuroscience

Lecturer in Philosophy (Mind and Psychology) job with KINGS COLLEGE LONDON | 208131 – Times Higher Education (THE)

May 27, 2020 medical

The Philosophy Department at Kings College London is seeking an outstanding philosopher with research expertise and teaching experience in philosophy of mind and philosophy of psychology. Competence and ability to teach at all levels in philosophy of mind and philosophy of psychology are required.

The successful candidate will be involved in teaching philosophy modules in Neuroscience and the Mind and Advanced Topics in the Philosophy of Mind to students following the BSc in Neuroscience and other undergraduate courses in the Health Schools. Research specialization in philosophy of mind and/or philosophy of psychology is also required.

This is a permanent post to begin on 1 September 2020.

The selection process will include a presentation and a panel interview.

To apply, please register with the Kings College London application portal and complete your application online.

Please include with your application a recent piece of your research (either published or intended for publication) on a topic relevant to the post of no more than 5,000 words. This may be an indicated portion of a larger piece of work.

Please also ask three referees to send their letters by the closing date to Philosophy@kcl.ac.uk

Applicants should make clear in their supporting statement how they meet each of the selection criteria for the post using examples of their skills and experience. Thismay include experience gained in employment, education, or during career breaks (such as time out to care for dependants).

This advertisement does meet the requirements for a Certificate of Sponsorship under Home Office regulations and therefore the university will be able to offer sponsorship for this role.

Neuroscience

Fulbright grants awarded to 21 from Johns Hopkins – The Hub at Johns Hopkins

May 27, 2020 medical

ByHub staff report

Fulbright grants have been awarded to 21 students and alumni of Johns Hopkins University.

Named for U.S. Sen. J. William Fulbright, who sponsored legislation creating the prestigious scholarship, the Fulbright U.S. Student Program is the country's largest educational exchange program, offering opportunities for students and young professionals to meet, work, live with, and learn from the people of the host country. The program awards approximately 2,000 grants annually and operates in more than 140 countries worldwide.

More information about the Fulbright application process can be found on the website of the National Fellowships Program.

Winners of the Fulbright Open Study/Research Award design their own research or academic course of study in a specific country. The program aims to facilitate cultural exchange and promote mutual understanding by supporting study or research abroad.

This year's winners from Johns Hopkins are:

Karissa Avignon, a 2019 graduate in public health. Avignon was awarded a grant to complete a master's degree in health policy and equity at York University in Toronto, Canada. She is especially interested in the potential of trauma-informed care to improve outcomes for immigrant women in Canada and the United States. She plans to devote her free time to assisting women in poverty with career preparation through Dress for Success; volunteering with the new Toronto chapter of her service sorority, Delta Sigma Theta; and volunteering at a local nursing home.

Kristin Brig. A PhD student in the history of medicine, Brig won a grant to travel to South Africa for her dissertation research. She plans to work in local archives in Durban and East London to investigate colonial infrastructure and policies for water management in the 19th century, when these two South African port cities were hubs for immigration. When not carrying out her dissertation research, she intends to start a medical humanities club at her host university, the University of KwaZulu-Natal, and volunteer with Duzi-Umngeni, a conservation organization.

Kiana Boroumand. A December 2019 graduate in sociology and English with a minor in Latin American studies, Boroumand received a grant to earn a master's degree in socio-legal studies at the University of Bristol in England. She plans to focus on housing and gender. Outside her studies, she looks forward to volunteering with the campus chapter of Lawyers Without Borders, helping tenants at the Bristol Law Center, and engaging the local arts scene through the Trinity Arts Community.

Emily Friedman, a PhD student in art history. Friedman won a grant to travel to France to carry out dissertation research on how the interactions of artists with scientists in the French town Lyon during the Renaissance prompted those artists to develop a distinctive and pragmatic theory of art-making. Her plans for community engagement in Lyon include volunteering at a museum, taking cooking classes, and joining a running club.

Eillen Martinez, a 2020 graduate in medicine, science, and the humanities. Martinez was awarded an arts grant to produce short stories in Spanish and English about immigrants from Venezuela arriving in Pamplona, a Colombian border town, and the mostly welcoming responses they have received from Colombians. Beyond her writing project, her plans to build relationships in Pamplona include helping run a writing workshop at her host university, the University of Pamplona; volunteering with the local Red Cross; and teaching swimming.

Mackenzie Mills, a 2020 graduate in Earth and planetary sciences. Mills received a grant to study the surface regeneration of icy satellites in the outer solar system as an affiliate of the Institute of Planetary Research of the German Aerospace Center in Berlin. Her intentions for her free time include language study and geology coursework at Freie Universitt Berlin and adding traditional German styles to her dance repertoire.

Kenneth Valles, an MPH candidate at the Bloomberg School of Public Health and an MD/PhD student at the Mayo Clinic. Valles won a grant to mine uniquely valuable health and migrant registry data in Sweden to explore the increased prevalence of viral hepatitis in Europe and the United States with changing immigration patterns. While living in rebro, Sweden, he looks forward to teaching English to migrants, joining the Swedish Alpine Club, and taking classes in Swedish language and culture.

Ronald Wang, a 2020 graduate in neuroscience. Wang received a grant to work at the Jagiellonian University in Krakw, Poland, on developing a cell model of Duchenne Muscular Dystrophy, an inherited neuromuscular disorder. He is excited to participate in Fulbright-sponsored seminars and plans to devote his free time to volunteering at the Children Friend's Society and, at the university, joining the Slowianski Song and Dance Ensemble and participating in the neuroscience forum.

Anna Weerasinghe, a PhD candidate in the history of medicine. Weerasinghe won a grant to pursue research in diverse, underutilized archives in Goa, India on the healing labor of Indian and mestia women in the early modern Portuguese colonial era, as part of her dissertation on how these women served as cultural intermediaries and medical knowledge-brokers. During her year in the Indian city of Panaji, she looks forward to participating in interdisciplinary seminars at the University of Goa, getting to know fellow distance runners in the Sossegado Runners club, and learning more Marathi and Konkani.

Courtney Whilden, a 2020 graduate in neuroscience. Whilden received a grant to study what genes individual neurons express in the development of the vestibulospinal system, which governs balance, at the University of Oslo in Norway. Her plans for making the most of her time in Oslo include joining the university's running club and "Coffeereads" book club, and learning more about the progressivism for which Norway is renowned by volunteering with Queer Youth Oslo.

The Fulbright-Fogarty Awards in Public Health promote the expansion of public health and clinical research in resource-limited settings. Offered through a partnership between the Fulbright Program and the Fogarty International Center of the U.S. National Institutes of Health, the award carries the same benefits as the traditional Fulbright Study/Research grants and is designed for candidates who are currently enrolled in medical school or in a graduate-level program and who are interested in global health.

The Fulbright-Fogarty Award winner from Johns Hopkins is Holly Nishimura, a PhD student at the Bloomberg School of Public Health. Nishimura will carry out research in Rakai District, Uganda, examining men's roles in transactional sex partnerships and the association with higher rates of HIV transmission, thereby contributing to HIV prevention efforts. She will work in partnership with the Rakai Health Sciences Program, an affiliate of the Bloomberg School and the NIH. She looks forward to bonding with community members through attending church services in Kalisizo and organizing language exchanges to help those who wish to refine their English speaking skills.

The English Teaching Assistantship Awards program places Fulbright winners in classrooms around the world to provide assistance to the local English teachers and to serve as cultural ambassadors for the United States.

The winners of English Teaching Assistantship Awards from Johns Hopkins are:

Julia Dickson. After receiving her BA in international studies, Dickson will travel to Kyrgyzstan with the hopes of leading outreach through dance and outdoor activities alongside of teaching.

Jinzhao (Grace) Jiang. After completing her MEd in secondary education at the JHU School of Education, Georgetown alum Jiang will teach in the Netherlands, where she also hopes to share her passion for yoga and continue to pursue her love of the outdoors.

Emily Lee. A 2019 graduate with a BA in public health studies, Lee will bring her nursing love of healthcare and cooking with her to Malaysia, where she hopes to host potlucks and shadow the nurse at the school where she will be working as an English Teaching Assistant.

Emily Luo. After receiving her BA in cognitive science, Luo will travel to Taiwan, where, in addition to teaching, she hopes to engage with her community through calligraphy and music clubs.

Frances (Frannie) Rooney. A 2018 grad with a BA from the Writing Seminars, Rooney plans to share her love of film with her university students outside of the classroom in Spain, as well foster exchange between her communities in Spain and the United States.

Sumeet Sidhu. Upon completion of his MEd in educational studies and secondary education at the JHU School of Education, Sidhu will spend a year teaching and researching EMS systems in Poland, where he also hopes to connect with his host community through golf and cross country.

Shawn Singh. Upon certification from the JHU School of Education, Singh plans to create a musical exchange program with his students in Uzbekistan during his Fulbright year.

Julia Wargo. With both an MA and BA from Hopkins in hand, Wargo will teach secondary school in South Korea with the desire to connect with her host community through violin lessons and jewelry-making workshops.

Nathan Wertheimer. After receiving his BA in philosophy and earth and planetary sciences, Wertheimer will bring his outdoor teaching experience to Malaysia, where he hopes to lead educational hikes and coach sports teams outside of the classroom.

Bethany York, a 2019 alum with a BA in neuroscience. York will travel to Lithuania with the hopes of participating in a book club alongside of teaching, as well as shadowing physicians as part of a research project on Lithuanian health care.

Five additional students from Johns Hopkins were named alternates for Fulbright grants this year: senior Cole Cooper, a public health studies major; Sarah Jaklitsch, a 2019 MA graduate of the School of Education; Jacob Jameson, who is completing his teaching certification from the School of Education; Sonal Sharda, who possesses both an MA from the School of Public Health from 2019 and a BA in neuroscience from 2017 from Hopkins; and senior Katherine Wick, an international studies and history major.

See the article here:
Fulbright grants awarded to 21 from Johns Hopkins - The Hub at Johns Hopkins

Neuroscience

Healthcare Sales & Marketing Executive BJ Jones Joins LUNGevity Foundation’s Board of Directors – P&T Community

May 27, 2020 medical

WASHINGTON, May 26, 2020 /PRNewswire/ --LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, announced today that William "BJ" Jones, Chief Commercial Officer, Migraine and Common Disease at Biohaven Pharmaceuticals, has joined LUNGevity's Board of Directors. His extensive commercial leadership experience at pioneering companies in the healthcare industry will provide strategic insight and guidance to the Foundation in its work of changing outcomes for people with lung cancer.

BJ brings a global healthcare perspective with his experience in mass market product launches. His work successfully building and leading diverse teams across various therapeutic areas, including neuroscience, cardio-metabolic, respiratory, GI, and infectious disease, will assist LUNGevity in continuing to identify and address unmet patient needs in the lung cancer community.

"We are thrilled to have BJ join our Board," said Andrea Ferris, President and CEO of LUNGevity Foundation. "He is an innovative leader in the pharmaceutical industry with important patient insights and expansive marketing and sales management experience. We are excited to have his unique perspective and expertise to help achieve LUNGevity's mission."

BJ is a seasoned pharmaceutical executive with two decades of commercial and neuroscience expertise in large pharmaceutical companies and small biotech firms. BJ has held leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and NitroMed.

Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major. He provided threat assessments to NATO leadership as an Engineering Analyst in the Foreign Technology division and led cutting-edge research in the Artificial Intelligence in Training program as a Function Chief in the AF Human Systems Division.

He holds a BS in Human Factors Engineering from the U.S. Air Force Academy, an MS in Industrial Engineering from Texas A&M University, and an MBA from Stanford Graduate School of Business.

LUNGevity looks forward to working with BJ to help improve outcomes for people affected by lung cancer.

About LUNGevity Foundation

LUNGevity is the nation's leading lung cancer organization investing in lifesaving, translational research and providing support services and education for patients and caregivers. LUNGevity's goals are three-fold: (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.

LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease.LUNGevity's comprehensive resources include a medically vetted website, a toll-free HELPLine in partnership with CancerCare, a unique Lung Cancer Navigator app, peer-to-peer mentoring for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our Clinical Trial Finder tool, a Clinical Trial Ambassador program, and participation with EmergingMed.

Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, a four-star Charity Navigator organization, please visitwww.LUNGevity.org.

About Lung Cancer in the U.S.

View original content to download multimedia:http://www.prnewswire.com/news-releases/healthcare-sales--marketing-executive-bj-jones-joins-lungevity-foundations-board-of-directors-301065266.html

SOURCE LUNGevity Foundation

See the rest here:
Healthcare Sales & Marketing Executive BJ Jones Joins LUNGevity Foundation's Board of Directors - P&T Community

Neuroscience

Photo gallery The winners: Cool Science Images 2020 – University of Wisconsin-Madison

May 27, 2020 medical

Eyeball-licking geckos, wiggling brain cells and a whole planets worth of weather are among the winners in the University of WisconsinMadisons 10th Cool Science Image Contest.

The quality of the images and videos produced on campus by scientists and people passionate about science is always so impressive, says Terry Devitt, a judge and one of the founders of the contest. It is always a very hard job, but a very enjoyable one, to choose the best among them.

A panel of nine experienced artists, scientists and science communicators judged the scientific content and aesthetic and creative qualities of the 101 images and videos entered in the 2020 version of the contest, which began as part of The Why Files, one of the first popular science news websites.

Cameron Batchelor and Ethan Parrish, graduate students, Geoscience, for a look at the climate-describing bands of color in a slice of stalagmite.

Natalie Betz, associate director, UWMadison Master of Science in Biotechnology, and Anya Wolterman, Macalester College undergraduate geology student, for their section of rock from a rift in the Earths crust in the Lake Superior region.

Caitlin Carlson, graduate student, Department of Bacteriology, for a view of a pair of leaf cutter ants sniffing out each others pheromone thumbprint.

Collin Roland, graduate student, and Lucas Zoet, assistant professor, Department of Geoscience, for a birds-eye view of bluff erosion on the Lake Michigan shore.

Guilherme Gainett, graduate student, and Prashant P. Sharma, assistant professor, Department of Integrative Biology, for an electron micrograph of the spiny leg of a new species of spider.

Ran Zhang, scientist, and Dalton Griner, graduate student, Department of Medical Physics, for an X-ray of flowers used to test and improve mammograms.

Nisha Iyer, postdoctoral fellow, Wisconsin Institute for Discovery, for a picture of a crested gecko licking its own eyeball.

Robert Morgan, graduate student, and Keith Bechtol, assistant professor, Department of Physics, for a snapshot of thousands of distant galaxies made while hunting for the source of a single subatomic particle.

Michael Petersen, Edward Williams and Ray Collier, all staff of the Wisconsin Crop Innovation Center; and Frank McFarland, graduate student, Department of Agronomy, for their image of the first transgenic hemp plants.

Miranda R. Sun, research specialist, Department of Comparative Biosciences, for a brightly colored section of a developing mouse embryo.

Rick Kohrs, instrument technologist, Space Science and Engineering Center, whose animation of 90,000 satellite images shows a full year of Earths weather.

Chris Morrow and Tiaira Porter, graduate students, Department of Neuroscience, for a video capturing the movement of neural stem cells switching from dormancy to activity.

STORY CONTINUES AFTER GALLERY

1 This slice of stalagmite at 250,000 years old, the oldest dated stalagmite in the Midwest is being used to study the climate of ancient mid-continental North America. The colored layers reflect changes in soil above the cave in which the stalagmite formed, with rich soil (and thicker vegetation) revealed in deeper orange bands and less organic matter (and fewer plants) in light green.

Cameron Batchelor, and Ethan Parrish, graduate students, GeoscienceDigital camera

2 This thin section of troctolite, an igneous rock composed of feldspar and olivine, was collected near Duluth, Minnesota, from the Proterozoic Midcontinent Rift. The rift is a tear in the Earths crust caused by continental plates colliding in the Lake Superior region. Polarized light accentuates vivid colors.

Natalie Betz, associate director, UWMadison Master of Science in Biotechnology; Anya Wolterman, Macalester College undergraduate geology studentPetrographic microscope

3 Each colony of leaf cutter ants has a unique chemical thumbprint, a combination of pheromones that members of the colony can recognize as their own. These two Acromyrmex echinatior ants from different colonies are inspecting each others pheromone signatures.

Caitlin Carlson, graduate student, BacteriologyDigital camera with macro lens

4 Storm-driven Lake Michigan waves cut away bluffs in Warnimont Park in Cudahy, Wisconsin, while the freeze and thaw of seeping groundwater wear at the crest. Researchers study the intertwined effects of waves and groundwater on erosion with three-dimensional models of coastal bluffs based on overhead images captured by drone flights.

Collin Roland, graduate student, and Lucas Zoet, assistant professor, GeoscienceDJI Phantom 4 Advanced unmanned aerial vehicle

5 The spines armoring the leg of a tiny, newly described species of huntsman spider, Zalmoxis adze, are a remarkable work of sexual dimorphism theyre completely absent in females. While leg details were an important way to differentiate this spider as a new species, little is known about how the heavy spikes serve males in the leaf litter on the forest floor of Papua New Guinea. But it may be very showy or very violent.

Guilherme Gainett, graduate student, and Prashant P. Sharma, assistant professor, Integrative BiologyField emission scanning electron microscope

6 Flowers stand in for healthy breast tissue in this mammography image, while added calcifications Can you spot them all? represent the sort features doctors look for in X-ray images in an effort to catch breast cancer in early, treatable stages. UWMadison researchers are working to improve detection of patterns of tiny calcifications for faster, safer, more effective diagnosis.

Ran Zhang, scientist, and Dalton Griner, graduate student, Medical PhysicsSelenia Dimensions Mammography System

7 Crested geckos have clear, immovable eyelids, and a swipe of the tongue is the best way to keep them clean and moist. With veritable superpowers like the ability to see in the dark and climb vertical surfaces, geckos often serve as models for bio-inspired engineering.

Nisha Iyer, postdoctoral fellow, Wisconsin Institute for DiscoveryDigital camera

8 This snapshot of the sky contains thousands of distant galaxies, each containing billions of stars. The UWMadison physicists who made it were looking for the flash of the explosion of a single star, the potential source of a sub-atomic particle called a neutrino, spotted zipping through the Earth by the IceCube Neutrino Observatory at the South Pole. The distant galaxies, swirling billions of light years away, are all the harder to see because of nearby objects, like the pictured Helix Nebula.

Robert Morgan, graduate student, and Keith Bechtol, assistant professor, PhysicsDark Energy Camera and Victor M. Blanco Telescope

9 Thanks to a gene similar to one that makes some fish glow, leaves of the first transgenic that is, augmented with genes from another species hemp plants appear red when seen through a special filter, while leaves of an unaltered plant are a familiar green. Successfully engineering changes in hemp opens the door to alterations that could affect disease resistance, crop yield, fiber quality and cannabinoid compounds. It offers potential benefits for farmers, consumers and medical applications.

Michael Petersen, Edward Williams and Ray Collier, all staff of the Wisconsin Crop Innovation Center; and Frank McFarland, graduate student, AgronomySmartphone with specialized filter

10 This section of the head of an 11-day-old mouse embryo was expertly prepared to highlight blood vessels marked by the green and red of endothelial cells and laminin protein, respectively in the developing brain (the heart-shaped structure at the center). The vessels are particularly dense at the lower end of the two black slits that will become nostrils, where tissue is fusing together to form the upper lip. If the tissue fails to fuse, the mouse will be left with a birth defect studied by the researchers in the lab that produced the image: a cleft lip.

Miranda R. Sun, research specialist, Comparative Biosciences, School of Veterinary MedicineEpifluorescence microscope

Combining more than 90,000 individual images taken by five satellites two American, one Japanese and two from the European Space Agency perched 22,000 miles above the Earth makes for an animated view of global weather patterns. Strong storms span many days, and seasonal shifts come and go as the sunlight over the poles waxes and wanes and the planet spins from March 2019 to March 2020.

Rick Kohrs, instrument technologist, Space Science and Engineering CenterGeostationary satellites

Neural stem cells switch from a dormant to an active very active, in many cases state in this video from the lab of Neuroscience Professor Darcie Moore. The vigorous wigglers are starting a protein-maintenance program critical for efficient activation and differentiation into health brain cells.

Chris Morrow and Tiaira Porter, graduate students, NeuroscienceConfocal microscope

CONTINUED FROM ABOVE

There was enthusiastic support right out of the gate, and that enthusiasm has grown year after year, says Devitt, once editor of The Why Files and the recently retired director of research communications at UWMadison. Sharing science through imagery is another way to show how science works, and what you can learn from getting a close-up view of nature. And we all love to see something new and amazing.

The contest winners along with a slideshow of all entries are typically displayed each fall in the McPherson Eye Research Institutes Mandelbaum & Albert Family Vision Gallery on the ninth floor of the Wisconsin Institutes for Medical Research, 1111 Highland Ave. An exhibit will be scheduled and announced as activity on campus allows.

The 2020 winners show off the breadth of research and technical and scientific expertise at UWMadison. The images were captured by experts in their scientific fields, trainees, students and curious amateurs, using flying drones, smartphones, cutting-edge electron microscopes and Earth-facing satellites orbiting tens of thousands of miles away.

Their subjects are both everyday and ephemeral, large enough to encompass billions of stars, and more minuscule than an ant.

The Cool Science Image Contest helps recognize the technical and creative skills required to capture images or video that document science or nature, and benefits from sponsorship by Madisons Promega Corp., with additional support from DoIT Digital Publishing and Printing Services and the UWMadison Division of the Arts.

Winning entries are shared widely on UWMadison websites and in public exhibitions, and all entries are showcased in a slide show at the Wisconsin Science Festival.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Continue reading here:
Photo gallery The winners: Cool Science Images 2020 - University of Wisconsin-Madison